Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse

J. Krug; E. F. Lampeter; A. J. K. Williams; E. Procaccini; C. Cartledge; A. Signore; P. E. Beales; P. Pozzilli

doi:10.1055/s-2007-1003240

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 1992; 24(1): 1-4
DOI: 10.1055/s-2007-1003240

Originals

Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse

J. Krug¹ ^, ⁴ , E. F. Lampeter¹ , A. J. K. Williams¹ , E. Procaccini³ , C. Cartledge² , A. Signore³ , P. E. Beales¹ , P. Pozzilli¹ ^, ³

¹Department of Diabetes and Metabolism, St. Bartholomew's Hospital, United Kingdom
²Department of Chemical Pathology, St. Bartholomew's Hospital, London, United Kingdom
³Cattedra Endocrinologia (I), Clinica Medica II, University of Rome “La Sapienza”, Rome, Italy
⁴Stadtkrankenhaus Leipzig, Leipzig, Germany

Abstract

PDF Download

Summary

Ciamexon (CMX), a new immunomodulatory compound acting mainly on B-lymphocytes was given orally to 42 NOD mice divided into three sex and litter matched groups (A: 0.3 mg/mouse/day CMX, B: 1.5 mg/mouse/day CMX, C: control) from 7 weeks of age. Animals were followed up for evaluation of diabetes incidence up to 32 weeks of age. There was a tendency for a delayed onset of hyperglycemia in mice of group B up to 26 weeks of age; however no significant difference in the cumulative incidence of diabetes at 32 weeks of age was observed (A: 57.5%, B: 38.5%, C: 38.5%). No differences were found in the number of infiltrated islets in animals culled at 10 weeks of age treated with CMX from 4 weeks of age.

We conclude that CMX does not modify the course of insulitis and diabetes incidence in NOD mice although the appearance of glycosuria was delayed by this treatment.

Key words

NOD Mouse - Type 1 Diabetes - Immunotherapy of Type 1 Diabetes - Ciamexone

PDF (330 kb)